Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Urogen Pharma Ltd (NQ: URGN )

13.45 -0.40 (-2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 424,250
Open 13.85
Bid (Size) 13.20 (1)
Ask (Size) 14.70 (2)
Prev. Close 13.85
Today's Range 13.15 - 14.26
52wk Range 8.690 - 24.13
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
From UroGen Pharma Ltd.
Via Business Wire

Performance

YTD
-11.57%
-11.57%
1 Month
+1.82%
+1.82%
3 Month
-15.88%
-15.88%
6 Month
+17.88%
+17.88%
1 Year
+8.38%
+8.38%

More News

Read More
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
From UroGen Pharma Ltd.
Via Business Wire
Earnings Outlook For UroGen Pharma
Via Benzinga
Recap: UroGen Pharma Q3 Earnings
Via Benzinga
Preview: UroGen Pharma's Earnings
Via Benzinga
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
From UroGen Pharma Ltd.
Via Business Wire
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Earnings Scheduled For March 14, 2024
Via Benzinga
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Via Benzinga
UroGen Pharma Reports Third Quarter 2023 Financial Results
From UroGen Pharma Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.